MMSI — Merit Medical Systems, Inc.

Merit Medical Systems (MMSI) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $393.9 million, up 11% year-over-year (10% on a constant currency basis).
• Organic Growth: 6.6% in Q4, exceeding guidance expectations.
• Non-GAAP Operating Margin: Increased to 21%, up 138 basis points year-over-year.
• Non-GAAP EPS: Grew 12% to $1.04, exceeding guidance by $1.8 million.
• Free Cash Flow: $74 million in Q4, a 13% increase year-over-year, marking a quarterly record.
• Full Year 2025 Performance: Constant currency revenue growth of 11%, non-GAAP operating margin of 20.3%, and free cash flow of nearly $216 million.

2. Strategic Updates and Business Highlights:

• The company is focused on executing its growth initiatives and successfully integrating acquisitions, including lead management products and the C2 CryoBalloon device.
• Merit Medical is transitioning from a founder-led to a founder-inspired organization, enhancing collaboration across global teams.
• The divestiture of the DualCap product line for $28 million is expected to free up resources for higher-margin products.
• The company emphasizes a strong portfolio of foundational and therapeutic products, with a commitment to innovation and strategic M&A.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected growth of 6% to 8% (5% to 7% on a constant currency basis), with contributions from recent acquisitions.
• Non-GAAP EPS Guidance for 2026: Projected between $4.01 and $4.15, reflecting 5% to 8% growth year-over-year.
• Free Cash Flow Guidance: Minimum of $200 million for 2026, with planned capital expenditures of approximately $90 million.
• Q1 2026 Revenue Guidance: Anticipated between $375 million and $380 million, representing 6% to 7% growth year-over-year.

4. Bad News, Challenges, or Points of Concern:

• OEM Sales Decline: OEM product sales decreased by 15% in Q4, attributed to inventory destocking and macroeconomic pressures, particularly in international markets.
• Tariff Impact: Expected to have a significant impact on margins, with a projected $15 million effect on non-GAAP EPS for 2026.
• China Market Challenges: Continued issues with volume-based purchasing and a decline in sales, which may impact future growth.
• Q1 Margin Concerns: Non-GAAP operating margins expected to decline due to increased expenses and tariff impacts, with a projected range of 16.7% to 18.5%.

5. Notable Q&A Insights:

• Gross Margin Drivers: Continued focus on product mix, pricing discipline, and cost management are critical for maintaining gross margin improvements.
• Rhapsody Product Launch: Initial revenue expectations for Rhapsody are set at $7 million for 2026, with the sales team actively pursuing both hospital and non-hospital accounts.
• M&A Strategy: Merit is open to pursuing larger acquisitions than in the past, focusing on both foundational and therapeutic products to enhance growth.
• Q1 Growth Drivers: Anticipated slower growth in Q1 due to OEM performance, macroeconomic factors, and ongoing supply chain challenges, with expectations for improvement in subsequent quarters.

Overall, Merit Medical reported strong financial results for Q4 2025 and provided optimistic guidance for 2026, despite facing challenges in OEM sales and external economic pressures. The company is strategically positioned for growth through innovation and acquisitions while managing operational efficiencies.